Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group.
Han HS, Lee KE, Suh YJ, Jee HJ, Kim BJ, Kim HS, Lee KW, Ryu MH, Baek SK, Park IH, Ahn HK, Jeong JH, Kim MH, Lee DH, Kim S, Moon H, Son S, Byun JH, Kim DS, An H, Park YH, Zang DY. Han HS, et al. Among authors: ryu mh. Ther Adv Med Oncol. 2022 Nov 2;14:17588359221132628. doi: 10.1177/17588359221132628. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36339930 Free PMC article.
Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, Lee KH, Oh SJ, Kim YK, Suh CW, Heo DS, Ryoo BY, Kim JK, Song HS, Lee WS, Kim HJ, Bang YJ, Yang SH, Sohn SK, Kang YK; Lymphoma Study Division of the Korean Cancer Study Group. Park YH, et al. Among authors: ryu mh. Ann Hematol. 2006 Apr;85(4):257-62. doi: 10.1007/s00277-005-0060-6. Epub 2006 Jan 17. Ann Hematol. 2006. PMID: 16416337
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Yamaguchi K, et al. Among authors: ryu mh. J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15. J Clin Oncol. 2023. PMID: 36379002 Free PMC article. Clinical Trial.
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).
Lee KW, Zang DY, Ryu MH, Han HS, Kim KH, Kim MJ, Koh SA, Lee SS, Koo DH, Ko YH, Sohn BS, Kim JW, Park JH, Nam BH, Choi IS. Lee KW, et al. Among authors: ryu mh. Cancer Res Treat. 2023 Oct;55(4):1250-1260. doi: 10.4143/crt.2023.333. Epub 2023 May 25. Cancer Res Treat. 2023. PMID: 37232070 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. Among authors: ryu mh. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Kang YK, Ryu MH, Di Bartolomeo M, Chau I, Yoon H, Kim JG, Lee KW, Oh SC, Takashima A, Kryzhanivska A, Chao Y, Evesque L, Schenker M, McGinn A, Zhao Y, Lee J, Wyrwicz L, Boku N. Kang YK, et al. Among authors: ryu mh. Gastric Cancer. 2024 Mar;27(2):375-386. doi: 10.1007/s10120-023-01455-5. Epub 2024 Jan 28. Gastric Cancer. 2024. PMID: 38281295 Free PMC article. Clinical Trial.
404 results